Many progresses for the treatment of multiple myeloma have been made since last decade.The application of novel target agents has brought the treatment of multiple myeloma into a new era.The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents.It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined.In this review,the author will review the current status and make a prospective discussion in this field.

In present study,we detected HLA-DR antigens on monocytes of 28 patients with mutiplemyelomas (MM) and 20 normal controls with indirect immunofluorescent staining and flow cy-tometric technique.It was descovered that HLA-DR~+ monocytes of patients (33.63?16.24%)were greatly lower than these of normal controls (61.45?10.1% ) (P

Diagnostic Imaging ; Humans ; Multiple Myeloma ; diagnosis ; therapy

Humans ; Multiple Myeloma ; Neoplasm Recurrence, Local

Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; pathology ; therapy ; Neoplasm Staging ; Transplantation, Autologous

Purpose:To explore the in vitro effects of apoptosis induction of 2-methoxyestradiol(2ME2),an estrogen derivative on primary myeloma cells and hematopoietic precursors from multiple myeloma patients. Methods:The primary myeloma cells and hematopoietic precursors from 14 multiple myeloma patients were examined determine apoptosis cells in situ by terminal-deoxynucleotidyl transferase mediated dUTP nick end labeling(TUNEL)assay. Results:After co-cultured with different concentrations (1,4,16?mol/L) 2 ME2 for 48h respectively,apoptotic ratios of myeloma cells were 10.5? 1.2%,21.2?2.3%,36.8?3.6% respectively ,which shows a concentration- dependence.In comparision with the control group,the difference is of statistical significance(P0.05). Conclusions:2ME2 could electively induce apoptosis of primary myeloma cells from myeloma patients and has little apoptotic effect on granulocytic,erythrocytic and lymphocytic cells in the bone marrow.

According to the latest classification of International Myeloma Working Group(IMWG),multiple myeloma(MM)is roughly classified into two groups,asymptomatic myeloma(smoldering myeloma)and symptomatic myeloma.The former is equal to the stage Ⅰ of Durie-Salmon(DS),and patients of this type only wait and see,and do not need any therapy.The later is equal to stage Ⅱ and Ⅲ of DS,and patients of this type need therapy immediately.Autologous stem cell transplantation(ASCT)is recommended by National Comprehensive Cancer Network(NCCN)for patients with stage Ⅱ or Ⅲ myeloma with good performance status in 2007.Different therapeutic regiwen should he selected for newly diagnosed MM patients according to whether ASCT is suitable or not.

Multiple myeloma (MM) remains an incurable disease at present. In past decade, the efficacies of treatment and patients' survivals have been greatly improved due to the application of high dose chemotherapy followed by stem cell transplantation, novel agents and their combinations. To further improve the outcomes of patients with MM, we should emphasize on exploration of the new treatment strategies, individualization of regimens and development of new targets.

Multiple myeloma (MM) is one of hot topics in the 54th ASH annual meeting.There were over 700 myeloma related abstracts in 2012.The abstracts reflected recent progress of MM researches and fell into 4 major groups,including new drug trials,frontline options,biology and molecular genetics,and myelodysplastic syndrome prior to the onset of myeloma and myeloma treatment.

Multiple myeloma (MM) is a genetically complex disease that is becoming more common in today' s aging population.In the 18th European Hematology Association (EHA) annual meeting,there were a number of key topics focusing on the development of MM from intraclonal heterogeneity,novel therapeutic agents,and relapse and refractory MM therapy,etc.